ACXP

Acurx Pharmaceuticals LLC

ACXP.US acurxpharma.com
1.40
-0.01 (-0.36%)
USD · NASDAQ
52-week range
1.31
8.34
Trading at 1% of the 52-week range
Market Cap
6.02M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
1.74
Div. Yield
N/A
% Institutions
3.71%
% Insiders
2.35%

1 Year

-67.2%

3 Year

-96.0%

10 Year

-99.1%
Description

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Company Information

Company Name
Acurx Pharmaceuticals LLC
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US00510M2035
CIK: 0001736243
CUSIP: 00510M104
Currency: USD
Full Time Employees: 4
Phone: 917 533 1469
Fiscal Year End: December
IPO Date: Jun 25, 2021
Description:

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Address:

259 Liberty Avenue, Staten Island, NY, United States, 10305

People

Directors & Officers

Name Title Year Born
Mr. Robert J. DeLuccia Co-Founder & Executive Chairman 1946
Mr. David P. Luci C.P.A., Esq., J.D. Co-Founder, President, CEO, Corporate Secretary & Director 1967
Mr. Robert G. Shawah C.P.A. Co-Founder & CFO 1967
Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. Medical Director 1948

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 06, 2025 David P Luci N/A Purchase 2.46K $20.20 $49.75K
Jan 06, 2025 Joseph C Scodari N/A Purchase 1.23K $20.20 $24.87K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Jane Street Group LLC 54.64K Mar 31, 2026 1.04% $0.00 408.63%
Vanguard Capital Management, LLC 31.10K Mar 31, 2026 0.59% $0.00 0.00%
Geode Capital Management, LLC 24.82K Mar 31, 2026 0.47% $0.00 99.88%
CAMBRIDGE Invest RESEARCH ADVISORS, INC. 20.00K Mar 31, 2026 0.38% $0.00 0.00%
Vanguard Fiduciary Trust Co 16.21K Mar 31, 2026 0.31% $0.00 0.00%
Prospect Financial Services Llc 13.79K Jun 30, 2026 0.26% $0.01 0.00%
Morgan Stanley - Brokerage Accounts 6.50K Mar 31, 2026 0.12% $0.00 0.00%
UBS Group AG 6.31K Mar 31, 2026 0.12% $0.00 3,634.91%
Wells Fargo & Co 2.30K Mar 31, 2026 0.04% $0.00 0.00%
Westside Investment Management, Inc. 1.65K Mar 31, 2026 0.03% $0.00 0.00%
Nbc Securities Inc 1.50K Mar 31, 2026 0.03% $0.00 0.00%
Western Wealth Management, LLC 1.33K Mar 31, 2026 0.03% $0.00 0.00%
Tower Research Capital LLC 1.03K Mar 31, 2026 0.02% $0.00 -64.26%
MCGUIRE CAPITAL ADVISORS INC 1.00K Mar 31, 2026 0.02% $0.00 0.00%
Barclays PLC 380.00 Mar 31, 2026 0.01% $0.00 0.00%
Group One Trading, LLC 245.00 Mar 31, 2026 0.00% $0.00 -13.43%
Cornerstone Planning Group LLC 167.00 Mar 31, 2026 0.00% $0.00 0.00%
Advisor Group Holdings, Inc. 100.00 Mar 31, 2026 0.00% $0.00 0.00%
BlackRock Inc 60.00 Mar 31, 2026 0.00% $0.00 0.00%
SBI Securities Co Ltd 6.00 Mar 31, 2026 0.00% $0.00 -53.85%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Institutional Extnd Mkt Idx Tr 31.10K 0.57% ▲ 0.00% Jul 31, 2026
2 Fidelity Extended Market Index 21.37K 0.39% ▲ 0.00% Jul 31, 2026
3 Fidelity Series Total Market Index 2.98K 0.05% ▲ 0.00% Jul 31, 2026
4 Northern Trust Extended Eq Market Idx 2.77K 0.05% ▲ 0.00% Jun 30, 2026
5 NT Ext Equity Mkt Index Fund - Lending 2.77K 0.05% ▲ 0.00% Jun 30, 2026
6 NT Ext Equity Mkt Index Fund - NL 2.64K 0.05% ▲ 563.32% Jun 30, 2026
7 NT Ext Equity Mkt Idx Fd - DC - NL - T2 1.92K 0.04% ▲ 513.78% Jun 30, 2026
8 NT Ext Eq Mkt Idx Fd DC Lending Tier 5 1.09K 0.02% ▼ 83.09% Mar 31, 2026
9 Spartan Total Market Index Pool A1 1.06K 0.02% ▲ 0.00% Jul 31, 2026
10 Fidelity Total Market Index 1.00K 0.02% ▲ 0.00% Jul 31, 2026

Financial Highlights

Market Cap: $6.02M
Book Value: $1.74
Earnings/Share: $-2.44
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -55.92%
ROE (TTM): -128.11%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $-4.64M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 4.30M
Shares Float: 5.14M
% Insiders: 2.35%
% Institutions: 3.71%
Short % Float: 2.90%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-6.26B
R&D
adjust
$-1.83B
Operating Income
subtotal
$-8.09M
Other / Non-Operating Items
adjust
$125.45K
Net Income
subtotal
$-7.97M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ACXP.US!